Special Issue

Recent Advance of Pulmonary Vascular Functions and Mechanisms in Biology and Disease

Message from the Guest Editor

Pulmonary vasculature is composed of many different types of cells including smooth muscle, endothelial. fibroblast, pericyte, inflammatory, stem, progenitor, other cells. Each type of cells may play unique important functional roles in pulmonary vascular biology and diseases. The roles of each type of cells is likely to be mediated by one or multiple molecules and their associated singling pathways. Evidently, significant progress has been made in this research field. As a result, it is necessary to offer a widespread and comprehensive recent advances in the studies of pulmonary vascular functions and mechanisms in biology and disease. These valuable advances may not only enhance current basic, translational and clinical research, but also promote to identify new drug targets and therapies.

Guest Editor

Dr. Yongxiao Wang

Department of Molecular and Cellular Physiology, Albany Meidcal College, Albany, NY, USA

Deadline for manuscript submissions

closed (31 May 2024)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/124535

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).